| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 440.83 | 3.9% |
| Total Income | 465.14 | 4.3% |
| Expenditure | 344.56 | 3.0% |
| PBT | 120.57 | 8.1% |
| Net Profit | 91.83 | 7.8% |
| OPM | 27.10% | 11.81pp |
| NPM | 19.74% | 1.02pp |
| EPS | 8.92 | 5.2% |
Poly Medicure Ltd Reports 21% FY 2025 Revenue Growth, 31% PAT Growth
07 May 2025 · 7 May 2025, 02:18 am
Summary
Poly Medicure Ltd, a leading Medical Device company, announced its audited consolidated and standalone financial results for the quarter and year ended on March 31st, 2025. The company reported a consolidated revenue growth of 21% and 17% for the full year and quarter ended March 31, 2025, respectively. The EBITDA grew by 26.6% and 23.8% for the full year and quarter ended March 31, 2025, respectively. The PAT grew by 31.1% and 34.3% for the full year and quarter ended March 31, 2025, respectively.
Key Highlights
- 1
Consolidated revenue growth of 21% in FY 2025
- 2
Q4 Core EBITDA margin at 27.1%
- 3
Revenue from operations increased by 17% in Q4 2025 compared to Q4 2024
- 4
EBITDA grew by 24% in Q4 2025 on a YoY basis
- 5
PAT increased by 34% in Q4 2025 compared to Q4 2024
- 6
FY 2025 Consolidated EBITDA growth of 27% on a YoY basis
- 7
Q4 and FY2025 domestic revenue growth was 24% and 19% respectively on a YoY basis
- 8
Renal division continues to gain market share in the domestic market with revenue growth of 69% and 60% in Q4 and FY2025 period respectively
- 9
EBITDA margins improved by 160BPS to 27% in Q4 2025
- 10
PAT margin expanded by almost 270BPS to 21% in Q4 2025
- 11
Balance sheet position remains strong with liquidity position of Rs. 1220crs as at March 25
- 12
Incurred a CAPEX of Rs. 325crs in FY 25
Management Comments
Mr. Himanshu Baid
Managing Director, Poly Medicure Limited
We are extremely pleased with our continued growth in the business in the Q4 and FY2025. Our margins continue to expand at higher scale of operations and that gives us immense confidence to keep investing capital to create additional manufacturing capacities. FY 2025 has been a transformative year for Polymed as we commercialised two new divisions, Cardiology and Critical Care. Our renal division continues to grow from strength to strength while the core infusion therapy consolidates its leadership position in clinically driven segments. The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. We believe that India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains. Our investment in 3 new plants is going on strongly, which we believe positions us very strongly to achieve the significant growth opportunities that lie in front of us.
Informational and educational content only. Not investment advice.